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Summary: The most important enzyme immunoassay techniques are described. The enzymes currently used as labels,
the methods of coupling them to antigens or haptens and the possible applications of these assays are reviewed.
Furthermore, an overview is given of the reliability and practicability of commercially available enzyme immunoassay
kits used in clinical chemical laboratories. Special consideration is given to possible interferences, the detection limits
and the mechanization of these tests. Various methods for curve-fitting are listed. It is concluded that most of the
currently commercially available enzyme immunoassays are suitable for routine application in appropriate centers
like clinical chemical laboratories of larger hospitals. The future role of enzyme immunoassays in clinical chemistry
is briefly discussed.
Enzymimmunotests in der Klinischen Chemie: Gegenwärtiger Stand und Entwicklungstendenzen
Zusammenfassung: Die wichtigsten Techniken des Enzymimmunotests werden beschrieben. Es wird eine Übersicht
über die gegenwärtig zur Markierung verwendeten Enzyme, die Methoden zu deren Kopplung an Antigene oder Hap-
tene und die Anwendungsmöglichkeiten dieser Tests gegeben. Ferner wird über den gegenwärtigen Stand der Zuver-
lässigkeit und Praktikabilität von käuflichen Enzymimmunotests berichtet, welche in klinisch-chemischen Labora-
torien angewendet werden. Besondere Berücksichtigung finden die möglichen Interferenzen, die Nachweisgrenzen
und Verfahren zur Mechanisierung dieser Tests. Verschiedene mathematische Methoden zur Ermittlung der Ergebnis-
werte sind aufgeführt. Es wird gefolgert, daß die meisten der zur Zeit käuflichen Enzymimmunotests für die routine-
mäßige Anwendung in geeigneten Zentren, wie z. B. klinisch-chemischen Laboratorien größerer Kliniken, geeignet
sind. Die zukünftige Rolle der Enzymimmunotests in der Klinischen Chemie wird kurz diskutiert.
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Antibody-induced inactivation of the enzyme
Antibody-induced reactivation of the enzyme
Fig. 1. Principles of the homogeneous enzyme immünoassays
(EMIT). All reactants are present in one reaction medium.
H hap ten, E-H enzyme labeled hap ten, AB limited
amount of antibody, i inhibition of the "marker
enzyme", S substrate and P product of the enzymic
reaction.
Fig. 2. Principles of heterogeneous enzyme immünoassays
(ELISA).
A antigen, E-A enzyme labeled antigen, E-AB enzyme
labeled antibody, AB and AB antibody against antigen
or hapten under test, AB2 antibody directed against the
immunoglobulin of the species, which was immunized
with the antigen to be determined.
Competitive enzyme immunoassay
2.1.1
2.1.2
Immuno-enzymometric assay
2.2
Competitive sandwich assay
2.3
Sandwich antigen assay
2.4.1
2.4.2
Sandwich antibody assay
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classification and schematic representation of the most
important assay principles.
Competitive procedures, in which a separation step is
avoided, are referred to as homogeneous enzyme
immunoassays. In these tests, which are commercially
available under the trade name "EMIT"2), the enzymatic
activity of the hap ten-enzyme conjugate is influenced
by the antigen-antibody reaction (4). In the first type
of these assays (fig. 1.1) the activity of the marker
enzyme is reduced, if the hapten-enzyme conjugate is
coupled to the antibody.
It is assumed that the antibody reduces the affinity of
the substrate to the active site of the enzyme, either by
steric hindrance (fig. 1.1) or by a conformational change
of the enzyme, or by prevention of conformational
changes necessary for catalytic activity (4, 20, 21, 27).
A further procedure of the EMIT is based on an inhibi-
tion of the marker enzyme by the coupled hapten
(fig. 1.2). The marker enzyme is reactivated, if the
antibody to the corresponding hapten is bound to the
hapten-enzyme conjugate. So far this technique has
only been used for the determination of thyroxine (28).
With both procedures the enzyme activity determined
depends on the concentration of the free hapten in the
sample. The technique of the homogeneous enzyme
immunoassay is suitable especially for the detection of
haptens. Therefore these assays are widely used partic-
ularly for drug monitoring and the determination of
thyroxine. Recently, however, this principle was also
used for the detection of large molecules such as
staphylococcal enterotoxin B (29), immunoglobulins
(IgG, IgM) and serum albumin (30).
Other competitive procedures, in which coenzymes are
used to label the ligand (5,6), may also be classified äs
homogeneous enzyme immunoassays. If the ligand-co-
enzyme conjugate is bound to an antibody, its cycling
in a suitable enzymic cycle is proportionally reduced.
This inhibition is reversed by unconjugated ligands in
competitive binding reactions. The cycling rates are
determined by spectrophotometric measurement of a
reaction product (5), or of the unbound ligand-cpenzyme
conjugate by a highly sensitive bioluminescent reaction
employing luciferase (EC 1.2.0.0.) from photobacterium
fisheri (6). So far, however, this assay principle has
gained no significance in clinical diagnosis.
Assay systems, in which the enzymic activity of the
conjugate is not influenced by the antigen-antibody-
reactipn, require a separation step and are called hetero-
geneous enzyme immunoassays; if solid^phase systems
are used for the separation of free and bound labeled
molecules, the procedure is called an enzyme-linked
immunosorbent assay (ELISA). These procedures allow
the determination of haptens and antigens.
The competitive enzyme immunoassay (fig. 2.1.1) is
analogous to the well known classical radioimmunoassay
of Yalow&Berson (1). Labeled and unlabeled antigens
compete for the binding sites of a limited amount of
antibody. As in the competitive homogeneous enzyme
immunoassay, saturation of the antibody occurs simulta-
neously, providing all reactants are incubated together.
This procedure is used with several commercial tests: for
example, in the ENZYMUN3) digoxin and thyroxine
assays (31,32).
The principle of "sequential saturation" is preferred
under certain conditions, e. g. if antigens with very low
serum concentrations such as insulin and thyrotropin
are to be determined (33-35). According to Pratt et al.
this technique, however, leads to reduced specificity (36).
Owing to the size and other properties of the enzyme
label relative to the antigen or antibody, the systems
used are mostly solid-phase; for example, antibody
coated polystyrene tubes, cellulose and recently also
magnetic polyacrylamide agarose particles have been
used for the separation of bound and free enzyme-con-
jugate (21, 22, 37).
Recently an enzyme immunoassay for the determination
of thyrotropin has been developed (35,179), in which the
immune complex formed is precipitated by a second
antibody. If the second antibody used for the separation
step is bound to a solid phase (fig. 2.1.2), the procedure
is called a double antibody solid phase (DASP) technique
(177).
Procedures in which the sample antigen is bound to an
enzyme-labeled antibody added in excess, are classified
as immuno-enzymometric assays (fig. 2.2). The remain-
ing, free labeled antibody is separated by binding with
antigen coupled to a solid phase, which is added in
excess.
In a further procedure, which has also been called a
competitive "sandwich" assay (26), labeled and un-
labeled antibody compete for the binding to an antigen,
which is bound to an antibody attached to a solid
phase (fig. 2.3). This method is used for the detection
of antibodies against HBs-antigen (22).
Non-competitive "sandwich" assays have been described
in numerous modifications (26). In the following only
the two most common techniques will be briefly
explained.
In the sandwich antigen assay an excess of antibody is
bound to a solid phase (fig. 2.4.1). The binding of the
antigen to the antibody is determined by use of labeled
antibody of the same specificity; therefore, it is
necessary that the antigen posses more than one anti-
genie determinant. Various commercial assays for the
detection of HBs-antigen and aj-fetoprotein are based
on this technique.
EMIT®: enzyme multiplied immunoassay technique.
3) ENZYMUN-TEST® = trade name for various heterogeneous
enzyme immunoassays.
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In a variation of this method, the bound antibody (ABj)
is indirectly labeled by a second enzyme4abeled antl·
body, which is directed against the first (AI^) and
should not react with the antibody (AB) attached to the
solid phase (fig. 2.4.2). The antibodies ABi and AB
should be obtained from different species. Such an in-
direct labelling can also be applied to the immuno-
enzymometric assay. The method of indirect labelling
has the advantage, that the corresponding enzyme-anti-
body conjugates, for a relatively universal application,
are commercially available. Thus the often difficult
direct labelling of the antibody may be circumvented.
In the sandwich antibody assay, the antibody to be
determined reacts with an antigen bound to the solid
phase, and is detected by a second enzyme-labeled anti-
body.
Enzymes used as labels
The quality of an enzyme imrriutioassay depends very
much on the purity of the antigen of hapten used for
immunization, calibration and conjugation, the specific-
ity of the antibody and the choice of a suitable enzyme
label. Sensitive assays require a highly purified enzyme
with a high'turnover number, and a low detection limit
for the reaction product (22).
The enzymes listed in table 1 arid 2, which are mainly
of vegetable and bacterial origin, have proved generally
useful. The enzymes most frequently used so far for
heterogeneous enzyme immunoassays are horse-radish
peroxidase, alkaline phosphatase and /J-J^galactosidase
(tab. 1).
The determination of the enzyme activity is chiefly
performed by photometry. In order to increase the
Tab. 1. Marker-enzymes for heterogeneous enzyme immunoassays (from data listed in 1. c. (15, 22, 38—40)).
Enzyme
Peroxidase
(EC 1.11. 1.7)
Alkaline phosphatase
(EC 3. 1.3.1)
0-jD-Galactosidase
(EC 3.2.1.23)
Glucoamylase
(EC 3.2.1.3)
Glucose oxidase
(EC 1.1.3.4)
Acetylcholinesterase
(EC 3.1. 1.7)
Catalase
(EC 1.11. 1.6)
Source
Horse-radish
Calf intestine
E. coli
E. coli
Rhizopus niveus
Aspergillus niger
Electrophorus electricus
Beef liver
Indicator
H2O2 /chromogen
H2O2/pyrogallol or luminolj
photon
Η2Ο2/ΚΙ/ΔΕ [mV]
p-Nitrophenol
o-Nitrophenol
4-Methylumbelliferone
Glucose/NADPH
H2 O2 /chromogen
[3H]Acetylcholin
H2O2/enthalpy
Analytical principle
Photometry
Luminescence measurement
Potentiometry
Photometry
Photometry
Fluorimetry
Fluorimetry
Photometry
Scintillation spectrometry
Thermometry
Tab. 2. Marker-enzymes for homogeneous enzyme immunoassays (from data listed in 1. c. (22, 29, 30)).
Enzyme
Lysozyme
(EC 3.2.1.17)
Malate dehydrogenase
(EC 1.1. 1.37)
Glucose-6-phosphate dehydrogenase
(EC 1.1. 1.49)
/3-D-Galactosidase
(EC 3.2.1.23)
/^Amylase
(EC 3.2.1.2)
Source
Chicken egg-white
Pig-he'af t mitochondria
Leuconostoc mesenteroides
E. coli
Potato
Indicator
Cell wall fragments of
Micrococcus luteus
NADH
NADH
Chromogen
Starch/reducing groups
Analytical principle
Turbidimetry
Photometry
Photometry
Photometry
Photometry
* X
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detectability of the assays, however, fluorogenic (41,
42,176,177,180), radioactive (43) and chemilumines-
cence producing substrates (38) are also used. In a newly
developed procedure, the activity of peroxidase bound
to an antibody-coated membrane is determined by an
iodide-sensitive electrode (39).
A thermometric enzyme immunoassay with adequate
sensitivity was recently described, in which the enthalpy
of the enzyrnic reaction is measured (40). In this assay,
a continuous flow system with immobilized antibodies
is used. At present this procedure has the disadvantage
of a low throughput of 10—20 samples/day and a large
specimen volume of 1 ml.
With the homogeneous enzyme immunoassays an NAD
dependent glucose-6-phosphate dehydrogenase from
Leuconostoc mesenteroides is mainly used. This enzyme
can be easily determined photometrically (tab. 2). A
turbidimetric procedure is applied for the determination
of the activity of lysozyme in the semiquantitative
EMIT for the detection of drug abuse (4). With the
newly developed EMIT for the determination of
proteins, j3-galactosidase is used as the enzyme label,
and a macromolecular chromogenic compound (not
further described by the authors) serves as substrate (30).
Coupling procedures
The choice of a coupling method depends primarily on
the molecule to be labeled. Enzyme-antigen or antibody
conjugates are usually prepared by glutaraldehyde or
periodate methods (22). The coupling of enzymes to
haptens is mostly carried out by formation of a peptide
bond between the carboxyl group of a hapten and an
amino group of an enzyme by use of the carbodiimide
or mixed anhydride method (22).
Area of application
The area of application of the enzyme immunoassay
corresponds largely to that of the radioimmunoassay.
Enzyme immunoassays can be performed with samples
of serum, plasma, urine and saliva.
For the detection of various drugs and hormones, a
number of commercial kits are already used in clinical
chemical routine laboratories. Furthermore assays for
the determination of plasma proteins, tumor antigens,
antigens of pathogenic organisms and antibodies have
been developed (22, 26).
Imprecision
The imprecision of enzyme immunoassays is of the
same order of magnitude as that of corresponding
radio immunoassays. According to our experience with ·.
most of the currently commercially available enzyme
immunoassays coefficients of variation from day to day
of about 2—10% could be achieved in the medium
measuring ränge, if duplicate determinations were
performed (tab. 3). However, the use of partly or fully
Tab. 3. Imprecision from day to day with commercially available
enzyme immunoassays.
Parameter
Phenobarbital
Phenytoin
Carbamazepine
Primidone
Ethosuximide
Theophylline
Methotrexate
Lidocaine
Digoxin
Thyroxine
Thyroxine
Binding Index
arFetoprotein
Insulin
Carcino-
embryonic
antigen
Triiodo-
thyronine
Assay
principle
EMIT
EMIT
EMIT
EMIT
ELISA
EMIT
ELISA
ELISA
ELISA
ELISA
ELISA
ELISA
Degree
of mechanization
Fully mechanized
Fully mechanized
Fully mechanized
Partly mechanized
Partly mechanized
Partly mechanized
Fully mechanized
Partly mechanized
Partly mechanized
Partly mechanized
Partly mechanized
Partly mechanized
Partly mechanized
Coeffi-
cient of
variation
(%)
2- 9
2-16
3
4- 7
4-10
3-12
4-11
4-11
5
5-10
11
6-22
5-16
Ref.
44,45
46
47
48,49
45
45
50
50
50
51
34
178
45
mechanized analytical systems, especially with the
EMIT, is a basic requirement for the attainment of
adequate precision (62, 92).
Inaccuracy
The inaccuracy of enzyme immunoassays is usually
examined by comparison of the results with those
obtained by other preferably non-immunological proce-
dures, such as gas-liquid chromatography, and by
recovery experiments. For many commercial enzyme
immunoassays extensive studies in this field have
already been published. The results of the EMIT for the
determination of theophylline, various antiepileptic
drugs and lidocaine were mainly in good agreement with
those obtained by uv-spectrophotometry (44, 52—56),
high-pressure liquid chromatography (53, 54, 57—61,
79) or gasJiquid chromatography (47-49, 56, 62-74,
79). In one study, however, highly significant differences
between the serum theophylline concentrations deter-
mined by EMIT and high-pressure liquid chromatography
were observed (80). An adequate correlation was found
between radioimmunoassays and EMIT for the measure-
ment of methotrexate (46) and thyroxine (50, 75—77)
and heterogeneous enzyme immunoassays for the deter-
mination of triiodothyronine (32,45), thyroxine (32,
50, 78), thyrotropin (35, 45,179), insulin (34, 114, 180),
total oestrogens (113), HB^-antigen (81, 82) and higher
concentrations of antibodies against HBS-antigen (83).
The comparison of enzyme immunoassays (EMIT,
ENZYMUN) and various radioimmunoassays for the
determination of digoxin with the radioimmunoassay
J. Clin. Chem. Clin. Biochem. / Vol. 18, 1980,A No. 4
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Tab. 4. Correlation of various radio- and enzyme immunoassay
kits with the Schwarz/Mann digoxin kit (12SI).
Kit
Radioimmunoassay * *)
Amersham
Beckman
Wellcome
Enzyme immunoassay
EMIT
ENZYMUN
Correla-
tion
coeffi-
cient
r
0.93
0.94
0.88 ·
0.90
0.91
Regression
constants*)
a
-0.16
-0.08
-0.13
-0.06
-0.13
b
1.12
0.94
0.96
1.01
1.09
56
80
69
130
91
*) Regression constants for the equation y = a + bx
**) 125I-labelled digoxin derivatives were used as tracer in all the
radioimmunoassay kits.
Ref. (84,165)
of Schwarz/Mann yielded comparable coefficients of
correlation and regression constants (tab. 4);
In about 2—3% of the specimens tested for digoxin
reproducible deviations of more than 30% were found
between the results of enzyme- and radioimmunoassays
(84). The cause of these discrepancies is not known. A
few authors (85) have reported an unsatisfactory correla-
tion between enzyme- and radioimmunoassays for the
determination of digoxin, but most authors have
reported a satisfactory correlation (84, 86—91, 165).
The results of the semiquäntitative EMIT for the detec-
tion of drug abuse in general agreed sufficiently with
those obtained by thin-layer chromatography (92-97),
gas-liquid chromatography (92) and a gas-chromato-
graphic-mass-spectrometric method (98). The efficiency
for the detection of barbiturates, amphetamine and
various opiates ranged from 75-98% (92, 93, 95-98).
Interferences
Enzyme immunoassays may be subject to interferences
due to distrubances of the enzymic or immunological
reaction.
Endogenous enzymes with similar biological effects to
the enzyme used as label, or other factors which directly
influence the enzymic reaction, may lead to wrong
results.
Thus lysozyme, which is used in the EMIT for the detec-
tion of drug abuse, is inhibited by high salt concentra-
tions in urine, various substances like heparin, leucine,
phenylalanine and cationic detergents, and by pH-values
outside of the range (5.5—8.0) recommended by the
manufacturer, all of which can cause false negative results
(99,100,172). Conversely, false positive results can be
found with this assay, due to an excretion of endo-
genous lysozyme (101). Most of these interferences can
be avoided by extraction of the specimen with an appro-
priate organic solvent and subsequent determination of
the drug in the reconstituted extract (96, 97, 172).
Horse radish peroxidase, an enzyme frequently used as
label in heterogeneous enzyme immunoassays, is prone to
inactivation by preservatives and other oxidative and
reducing agents (171). Therefore, several authors prefer
the use of alkaline phosphatase, especially for competi-
tive ELISA type assays (171).
With the ELISA-technique, interferences by light ab-
sorbing substances, such as hemoglobin, bilirubin or
turbidities or by endogenous enzymes or enzyme inhibi-
tors are reduced, if the activity of the bound enzyme
conjugate is measured. However, the washing-steps
required with this technique may theoretically influence
the imprecision of these assays considerably.
So far, in most of the homogeneous enzyme immuno-
assays for quantitative determinations in serum, only a
few cases of interference caused by the factors men-
tioned have been observed. An essential reason for this
appears to be the high, about 60 fold, dilution of the
serum sample in the reaction medium. Somewhat less
favourable conditions are only found with the EMIT
for the determination of digoxin (102) or thyroxine
(28,103). In order to achieve a sufficient detectability
with these procedure, the sample is diluted in the reac-
tion medium only 10 and 20 fold respectively. According
to the manufacturer of these assays the serum has to be
pretreated with 0.5 mol/1 NaOH in order to avoid inter-
ferences from certain serum proteins, such as lactate
or malate dehydrogenase.
Furthermore interferences can be caused by an un-
specific binding of the conjugate to the solid phase, or
by certain plasma proteins or transport proteins, which
compete with the antibody.
Cross-reactions with other compounds occur if the
antibody lacks specificity. According to our experience,
however, the antibodies of most commercial assays for
quantitative determinations show a relatively high
specificity (44,46,50, 62, 84).
The specificity of the EMIT and heterogeneous enzyme
immunoassays (ENZYMUN) for the determination of
digoxin corresponds to that of the radioimmunoassay
of Schwarz/Mann (tab. 5). Cross-reactions are observed
with structurally closely related compounds, such as
digitoxin, and various digoxin metabolites, such as
digoxigenin, digoxigenin-bis- and digoxigenin-morio-
digitoxoside. Canrenone and canrenoate, the major
metabolites of spironolactone, apparently do not cause
significant interference (84, 89,104,105).
In contrast to the enzyme immunoassays for quan-
titative determinations, most of the semiquäntitative
EMIT tests for the detection of drugs in urine show a
distinctly lower specificity (92, 93). Because of possible
interferences in these assays, all positive results must be
confirmed by a non-immunological method, For clinical
toxicölögical routine determinations it has'proved useful
J. Clin. Chem. Clin. Piochem. / Vol. 18,1980 / No. 4
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Tab. 5. Cross-reactivity of digoxin metabolites and various
cardiac glycosides*) in enzyme immunoassays (EMIT,
ENZYMUN) and a radioimmunoassay (Digoxin Kit
(125I), Schwarz/Mann) for determination of digoxin.
Compound EMIT ENZYMUN RIA
nmol/1**) nmol/1 nmol/1
Digoxin 1.28(100%) 1.28(100%) 1.28(100%)
Digoxigenin-bis- 1.54 ( 83%) 1.71 ( 75%) 1.37 ( 93%)
digitoxoside
Digoxigenin- 1.92 ( 67%) 2.13 ( 60%) 1.74 ( 74%)
mono-
digitoxoside
Digoxigenin 1.92 ( 67%) 3.20 ( 40%) 2.56 ( 50%)
Lanatoside C 2.03 ( 63%) 1.90 ( 66%) 2.03 ( 63%)
Digitoxin 13.07(10%) 12.42(10%) 11.90(11%)
Ouabain 16.47 ( 8%) 12.47(10%) 24.01 ( 5%)
*) Substances were added to drug-free human serum.
**) Concentration resulting in an absorbance or in counts per
minute equivalent to 1.28 nmol/1 digoxin. The ratio of
1.28 nmol/1 digoxin/corresponding concentration of the
compound tested is given in parenthesis.
yj £ / Ο A 1 4Γ C \Ref. (84, 165)
to perform a thin-layer Chromatographie screening test
and to use the EMIT as a confirmation analysis (92, 96,
97).
In the detection of barbiturates it was shown that the
predictive value for a positive result and the diagnostic
specificity were much higher when thin-layer chromato-
graphy and EMIT were used sequentially, than when the
tests were performed singly or in parallel (106).
Detection limits
The detectability of the enzyme immunoassay depends
on certain variables, such as the assay conditions, the
enzyme-substrate combination, the antigen and
especially the affinity of the antibody for the antigen
Tab. 6. Detection limits with various enzyme immunoassay kits.
Antigen/hap ten
1. Heterogeneous enzyme
immunoassays
HBs-antigen
Carcinoembryonic antigen
Ferritin
Thyrotropin**)
Insulin
aj-Fetoprotein
Oestriol
Digoxin
Thyioxine
2. Homogeneous enzyme
immunoassays (EMIT)
Digoxin
ThvroxineΛ iiy Awvuiw
Propranolol**)
Methotrexate
Phencyclidine
Methadone
Morphine
Diazepam
Oxazepam
Quinidine·
Propoxyphen
N-Acetylprocainamide
. Secobarbital
Tobramycin**)
Gentamicin
Theopyhlline
Amphetamine
Benzoyl Ecgonine
Phenytoin
Procainamide
Lidocaine
Carbamazepine
Primidone
Secobarbital**)
Valproic acid**)
Phenobarbital
Ethosuximide
Detection limit*)
(pmol/1)
0.9- 1.6
2.5
3.3
30.0
35.0
42.9
2.0 Χ 102
4.0 Χ 102
3.9 Χ 104
6.4 Χ 102
2.6 Χ 104
9.6 Χ 104
1.0 X 10s
0.3 Χ 106
0.6 Χ 106
1.1 X 106
1.1 X 106
1.4 Χ 106
1.4 Χ 106
1.5 Χ 106
1.8 Χ 106
2.1 Χ 106
2.1 Χ 106
2.1 Χ 106
2.8 Χ 106
1.4 Χ 107
3.0 Χ 106
3.1 Χ 106
4.0 Χ 106
9.9 Χ 106
4.2 Χ 106
4.3 Χ 106
8.5 Χ 106
1.1 X 107
1.3 Χ 107
1.7 Χ 107
2.2 Χ 107
7.1 Χ 107
Ref.
(22)
(112)
(110)
(179)
(34,114)
(51)
(113)
(89)
(78)
(102)
(75)V ' -J J(122)
(46)
(119)
(92)
(92)
(118)
(96)
(115)
(96)
(120)
(92)
(117)
(121)
(124)
(44)
(92)
(96)
(64)
(62)
(123)
(48)
(125)
(125)
(118)
(116)
(62)
(125)
body for labeled and unlabeled antigen have an un-
favourable effect on the detectability of the assay (107).
Nowadays the limits of detection for the enzyme immuno-
assay, based on various parameters, are already equal to
those of the radioimmunoassay. In general the detection
limits of the radioimmunpassays range from 1 —
500 pmol/1 or 0.2-50 fm l/ttibe (22). Comparable
detection limits were observed for example with hetero-
geneous enzyme immunoassays for the determination of
HBs-antigen and insulin (tab. 6). A recently described
enzyme immunoassay is capable of detecting even 1
attomol of ornitliine-5-aminotransferase (108, 109).
Other assays, for instance for the determination of
a^fetoprotein (51,11Ϊ) or digoxin show a detectability
which is more than five times lower than that of the
corresponding radioimmunoassays (22). Except for the
EMIT digoxin assay, the remaining homogeneous enzyme
immunoassays for the determination of drugs show a
comparatively low detectability (tab. 6), which, however,
*) Where data on the detection limit are not available, the
concentration of the lowest calibrator different from zero is
quoted instead of the detection limit, which actually may be
lower.
**) Reagents are not yet commercially available.
is sufficient for the detection of diagnostically relevant
serum or urine concentrations of these substances. The
advantage of working at a lower detectability is that
only very short periods of 30—150 seconds are necessary
for the measurement of the enzyme activities. Accord-
ingly in a series of 20 samples the time needed for a
determination (incubation periods included) is about
3-6 minutes by EMIT and 10-70 minutes by ELISA
type assays (tab. 7).
The detectability of homogeneous enzyme immuno-
assays can be increased, if the reaction of the enzyme-
drug conjugate with the antibody is stopped after a
short time by saturating the antibody with a larger
quantity of unlabeled drug (126).
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Tab. 7. Time required per determination with various enzyme
immunoassays.
Compound
Phenobarbital
Phenytoin
Carbamazepine
Primidone
Ethosuximide
Theophylline
Methotrexate
Digoxin
Thyroxine
Insulin
Assay principle
EMIT**)
EMIT***)
EMIT***)
ELISA***)
EMIT***)
ELISA***)
ELISA***)
Time
required
(min/
deter-
mina-
tion*)
3
4
6
9
3
13
68
Ref.
(44, 45, 62)
(46)
, (84)
(84)
(50)
(50)
(45)
*) duplicate determinations, incubation period included
**) number of different patient samples per series n = 30
***) n = 20
Mechanization
For routine application, the mechanization of enzyme
immunoassays appears to be of great importance (127).
The homogeneous enzyme immunoassays have very
favorable properties for mechanization; all reactants are
present in one reaction medium, the time for the
measurement of the enzyme activities is short and longer
incubation periods are avoided.
So far the analytical systems listed in table 8 have
proved useful for the mechanization of the EMIT. Photo-
meters equipped with thermally regulated flow-ceus in
combination with suitable dispensers and dilutors, and
centrifugal analyzers, are mainly used in partly
mechanized procedures. The use of fully mechanized
analytical systems for the determination of enzyme
activities has to be considered as a further step towards
rationalization of these assays. With an Eppendorf
system ACP 5040, for example, about 250 patient
samples can be analyzed by one technical assistant per
day, and the direct costs for technician time and reagents
Tab. 8. Mechanized procedures for the performance of EMIT assays.
1. Partly mechanized procedures
Gilford 300 N
Gilford Stasar III
Beckman 24/25
Beckman Trace III
Eppendorf 5085
Eppendorf 5090
Shimadzu UV-200
Miniature Centrifugal Analyzer
IL Multistat III MCA
Centrifichem
Gemsaec
LKB Reaction Rate Analyzer
Labtronic ES 25
Perkin-Elmer 124 D '
Kem-o-Mat
Aminco Rotochem II
ABA-100
2. Fully mechanized procedures
Eppendorf Analyzer 5010
Eppendorf System ACP 5040
Gilford 3500
ACA Du Pont
KDA American Monitor
Vitatron AKES
LKB Auto Chemist
KA-150 Perkin Elmer
SMA 12/60
Phenytoin, phenobarbital, primidone (63, 65,66), opiates (101)
Digoxin (86), theophylline (173)
Phenytoin, phenobarbital (56), primidone (69), digoxin (87), carbamazepine, ethosuximide (67)
Theophylline, phenobarbital (128)
Barbiturates, opiates, amphetamine, methadone, benzoyl ecgonine, oxazepam (92)
Digoxin (84)
Opiates (98)
Phenobarbital, phenytoin (129, 164), digoxin (130)
Theophylline, thyroxine (131,132), phenobarbital, phenytoin (131,132), opiates (133)
Phenytoin, pheriobarbital, primidone, carbamazepine, digoxin (90,134-136), theophylline (137)
Barbiturates, opiates, amphetamine, methadone (138), phenytoin (79,139, 140), phenobarbital
(79,140), theophylline, primidone, carbamazepine, ethosuximide (79)
Phenobarbital (141)
Digoxin (45)
Phenytoin (142)
Thyroxine (76)
Phenytoin (64), phenobarbital (150), theophylline (151)
Barbiturates, opiates, amphetamine, methadone, benzoyl ecgonine (143), phenytoin, phenobarbital
(144, 146), primidone, ethosuximide, carbamazepine (146), thyrqxirie (50, 77), digoxin (136),
theophylline (53), cortisol (145)
Phenytoin, phenobarbital (62), primidone, carbamazepine, ethosuximide, lidocaine (45), theo-
phylline (44), metho'tr'exate (46)
Phenobarbital (45), theophylline (173)
Phenytoin, phenobarbital, primidone, ethosuximide, carbamazepine (146), lidocaine (47)
Phenytoin, phenobarbital, carbamazepine, primidone, ethosuximide (147-149,166)
Opiates, amphetamine, methadone, barbiturate (152)
Phenytoin, phenobarbital, primidone, carbamazepine (153)
Thyroxine (75)
Phenytoin, phenobarbital, primidone (74), theophylline (52)
Thyroxine (154)
J. Clin. Chem. Clin. Biochem. / Vol. 18, 1980 / No. 4
Oellerich: Enzyme immunoassays in clinical chemistry 205
Tab. 9. Various analytical systems used for heterogeneous enzyme
immunoassays.
Eppendorf 5090
Eppendorf 5 091-A
Gilford EIA-PR 50
Abbott Quantum I
Titertek-Multiskan
LKB 2074
Zeiss PRP 8
Riele PMC Automatik
are about 50% lower than with the original procedure
(173).
For the rapid analysis of single emergency requests, the
ACA from DuPont apppears to be very suitable. With
this analytical system a calibration curve need not be
prepared for every run, providing the same lot of EMIT
tests is used (127,166). An emergency determination of
phenytoin, for example, takes about 15 minutes (166).
So far, however, only EMIT tests for the determination
of various antiepileptic drugs are available for this-
system.
Because of the long incubation periods, and the washing-
and separation steps, it is more difficult to mechanize
the ELISA-technique than the EMIT.
Certain steps, however, such as the washing procedure,
the dispensation of the reagents and the photometrical
measurement have already been mechanized (127).
Various analytical systems, which can be used to partly
mechanize heterogeneous enzyme immunoassays, are
listed in table 9. The newly developed system EIA-PR 50
from Gilford shows a relatively high degree of mechaniza-
tion and a good practicability. Antibody coated cuvettes
for this system are, however, are not yet commercially
available.
In our experience it was possible to coat the cuvettes
supplied with this system with an antibody directed
against thyroxine (45). Subsequently the coated cuvettes
were used in an enzyme immunoässay for the deter-
mination of this hormone (45).
Evaluation of the Results
Computers are used increasingly for the evaluation of
the results from enzyme immunoassays. The manual
procedures are lengthy, and sometimes less dependable.
Various methods may be used for curve-fitting (155—
162). These procedures are based either on certain
models or only on the data of the calibration points
(tab. 10). The most suitable method must first be
ascertained for each enzyme immunoassäy.
A weighted linear and non-linear regression after logit-
log transformation (156,158) and an empirical spline
interpolation (161) have proved to be useful for the
evaluation of the results obtained by the EMIT.
There are only limited data for the computer analysis
of results from the ELlSA-technique. With the ENZY-
MUN digoxiii assay, for example, a computer program
based on the parabolic regression has been used (162).
Tab. 10. Curve-fitting methods for enzyme immunoassäy.
1. Model-based methods
1.1 Parabolic regression (162)
1.2 Linear regression after logit-log transformation (156)
1.3 Weighted linear regression after logit-log transformation (156)
1.4 Weighted non-linear regression after logit-log transformation
(158)
2. Data-based methods
2.1 Manual curve-fit
2.2 Polygonal interpolation (156)
2.3 Empiric spline-interpolation (161)
2.4 Cubic spline-interpolation (156)
2.5 Spline approximation (159)
On principle all calibration curves calculated by a
computer should be checked visually.
A definitive recommendation of certain curve-fitting
methods for enzyme immunoassays cannot be given at
present, as extensive comparative studies with these
procedures are needed.
Conclusion
Most of the currently commercially available enzyme
immunoassays for the determination of haptens, such
as various drugs (44,46, 49, 62, 79, 84, 92, 93) and
thyroxine (50, 78), as well as HBs-antigen (81) have
already reached a stage of development, in which they
appear to be suitable for routine application in appro-
priate centers, such as the central laboratories of larger
hospitals. Despite their ease of operation, however,
these assays require certain experience ori the part of
the analyst, who must take account of a large number of
possible sources of interference.
The development of the enzyme immunoassäy is currently
still in a state of flux. It has to be expected that the
detectability, precision, specificity and practicability
of these assays will be further improved. Possible
sources of improvement lie in a better standardization
of the reagents and methods, the search for more
effective marker enzymes and the evaluation of alter-
native procedures for the determination of enzyme
activities, such as fluorimetry, luminescence photometry
and thermometry. A far-reaching mechanization of the
enzyme immunoassays appears to be essential. According
to existing experience, the improvement of the reliability
and practicability of these assays by mechanization is
likely to be far greater than the beneficial effects of
mechanization on the commonly used clinical chemi-
cal routine procedures. Furthermore the costs for
reagents and technician time can be considerably
reduced (44-46, 62,129,150,163,164, 173), if a
suitable mechanization is chosen.
•Recently enzyme immunoassays gained a relatively
great expansion in the area of therapeutic drug monitor-
ing, where procedures of a comparable simplicity and
specificity were not hitherto available. Using enzyme
J. Clin. Chem. Clin, Bioehem. /Vol. 18,1980 / No. 4
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immunoassays it has now become relatively easy to
introduce the monitoring of the serum concentrations
of various drugs, and the detection of drugs in urine
into the routine program of clinical chemical laboratories.
According to our experience there is an increasing
demand for such determinations. It has to be assumed
that this trend will continue.
Enzyme immunoassays are also increasingly used for
the determination of other parameters, such as various
hormones, HBg-antigen and antibodies. Further suitable
candidates for enzyme immunoassays are enzymes,
lipoproteins and bile acids (167-170,181). We believe
that iri the future enzyme immunoassays will gain
increasing importance in clinical chemistry.
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